Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06053411 · ClinicalTrials.gov registry record · Early Phase 1
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
A Early Phase 1 study of Interaction, sponsored by Washington State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06053411: Recruiting Early Phase 1 study of Interaction, sponsored by Washington State University.
NCT06053411 is a Early Phase 1 study of Interaction that is actively recruiting participants, run by Washington State University. The registered enrollment target is 30 participants, above the 19-participant average among 3 other Interaction trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06053411, a Early Phase 1 study of Interaction, is actively recruiting participants, sponsored by Washington State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug substrates.
Primary Outcome
Diclofenac AUC in UGT2B17 EMs
Conditions Studied
Interventions
- DRUG Diclofenac
- DIETARY_SUPPLEMENT curcumin
Study Locations (1)
Washington
- Washington State University College of Pharmacy and Pharmaceutical Sciences - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2026-08-18 |
| Phase | Early Phase 1 |
What NCT06053411 shows while recruiting
NCT06053411 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, above the 19-participant average among 3 other Interaction trials with a reported enrollment target (58% higher).
The record links to 1 condition, with Interaction appearing as the primary indexed condition, and to 2 interventions - of which Diclofenac is the first listed.
NCT06053411 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06053411 about?
NCT06053411 is a clinical study titled "Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac". The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin...
What is the current status of trial NCT06053411?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2024-03-01. Estimated completion is 2026-08-18.
What conditions does trial NCT06053411 study?
This clinical trial studies the following conditions: Interaction.
What interventions are being tested in trial NCT06053411?
The interventions under investigation include: Diclofenac (DRUG), curcumin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06053411?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06053411 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel
RECRUITING · Early Phase 1
-
Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
RECRUITING · Early Phase 1
-
The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI